

Effect of Diabetes Mellitus and Its Control on Myocardial Contractile Function in Rats

Bassem M. Alsawy^{1,3}, Magdi A. El-Damarawi^{2,3*}

¹Department of Physiology, Faculty of Medicine, Beni Swaif University, Cairo, Egypt; ²Department of Physiology, Faculty of Medicine, Tanta University, Tanta, Egypt; ³On Sabbatical leave to Department of Physiology, Faculty of Medicine, University of Tabuk, Saudi Arabia

Abstract

Citation: Alsawy BM, El-Damarawi MA. Effect of Diabetes Mellitus and Its Control on Myocardial Contractile Function in Rats. *OA Maced J Med Sci*. 2014 Sep 15; 2(3):431-438. <http://dx.doi.org/10.3889/oamjms.2014.074>

Key words: Diabetes mellitus; Thyroid dysfunction; Diabetic cardiomyopathy; Insulin; Rosiglitazone.

Correspondence: Dr. Magdi Ali El-Damarawi. Tanta University, Physiology, Tanta 12345, Egypt. Phone: 00201003889807. E-Mail: magdidamarawi@yahoo.com

Received: 13-May-2014; **Revised:** 20-Jun-2014; **Accepted:** 30-Jun-2014; **Online first:** 19-Jul-2014

Copyright: © 2014 Alsawy & El-Damarawi. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Competing Interests: The authors have declared that no competing interests exist.

AIM: This work was done to study the effect of both types of diabetes mellitus (DM) on myocardial contractility in rats. Also, we investigated the role of treatment of DM with insulin and rosiglitazone (used as treatment for type 1 and type 2 DM respectively) in improvement of myocardial dysfunction in diabetic rats.

METHODS: The study included 50 male Wistar albino rats, divided into 5 groups: control (group I), streptozotocin induced type 1 DM (group II), fructose induced type 2 DM (group III), insulin treated type 1 diabetic rats (group IV) and rosiglitazone treated type 2 diabetic rats (group V). At the end of the study, retro-orbital blood samples were withdrawn and blood glucose, plasma triglyceride (TG), total cholesterol (TC) and thyroid hormones levels were measured. Rats were then anesthetized and their hearts were excised and connected to Langendorff apparatus to perform mechanical cardiac performance tests including heart rate (HR), left ventricular developed pressure (LVDP) and maximum rate of pressure rise (+dp/dt).

RESULTS: Data of the study showed that relative to control group, there was significant increase in blood glucose, plasma TG and TC levels while, thyroid hormones and myocardial performance parameters showed significant decrease in both type 1 and type 2 diabetic rats. Treatment of type 1 diabetic rats with insulin and type 2 with rosiglitazone resulted in significant decrease in blood glucose, plasma TG and TC levels associated with significant improvement in thyroid hormones and myocardial performance parameters. The results also showed that insulin treatment of type 1 was more effective in ameliorating all parameters than treatment of type 2 by rosiglitazone.

CONCLUSION: We concluded that the induction of both types of diabetes resulted in decreased myocardial performance parameters. The treatment of type 1 and type 2 diabetes by insulin and oral rosiglitazone respectively improved to a great extent the altered metabolism and mechanical myocardial parameters, with more improving effect of insulin in type 1 than rosiglitazone in type 2 DM.

Introduction

Diabetes mellitus is a metabolic disorder characterized by the presence of hyperglycemia due to defective insulin secretion, defective insulin action or both. Patients with diabetes have a higher risk of cardiovascular events accounting for substantial premature morbidity and mortality [1]. Many studies in humans reported the existence of a diabetic cardiomyopathy (DCM). The underlying mechanisms of this cardiomyopathy are still incompletely understood because of experimental limitations in humans. Rodent models of type 1 and type 2 diabetes mellitus (DM) share several traits with human DCM and have greatly advanced the understanding of the underlying pathology of DCM [2]. Contractile dysfunction was observed in perfused hearts from diabetic mice. There was evident increase in left

ventricular end diastolic pressure and decreased left ventricular developing pressure, cardiac output and cardiac power [3]. Also, diabetes affects the thyroid hormones level and is thought to be associated with decreased serum levels of thyroid hormones {3,3',5-triiodo-L-thyronine (T3) and thyroxine (T4)}. Since insulin treatment improves both T3/T4 levels and β -adrenoceptor-mediated responses, it points out a possible relationship between insulin and thyroid hormones [4]. More importantly, left ventricular hypertrophy and diastolic dysfunction without hypertension in type 2 diabetics may be associated with elevated insulin resistance. The use of troglitazone (TRO) which is known to increase insulin sensitivity and decrease insulin resistance has resulted in an improvement in diastolic function [5]. Recently, the protective role of thyroid hormones was described in streptozotocin induced diabetes [6]. It

was reported that diabetes being associated with altered lipid metabolism, is commonly accompanied by thyroid dysfunction. This can produce significant metabolic disturbances that share in the mechanisms of DCM [7].

Accordingly in DM, hyperglycemia, disturbed thyroid functions and altered lipid metabolism may have a great role in the development of DCM and the correction of such disturbances will be very helpful in preventing its development. So, it is of extreme importance to evaluate the efficacy of management of DM in the correction of these changes and in prevention of DCM development and other cardiovascular complications.

The aim of the present work was to study the effect of induction of both types of DM on lipid profile and thyroid hormones plasma levels and the role of these metabolic disturbances in the development of DCM. Also, we investigated the role of treatment with insulin and rosiglitazone (used for treatment of type 1 and 2 DM respectively) in the control of these changes and in improvement of myocardial dysfunction in diabetic rats.

Material and Methods

Animals

Fifty adult male Wistar albino rats weighed between 200 – 250 g were housed in wire mesh cages at room temperature. Veterinary care was provided by local laboratory animal house unit in Faculty of Medicine, Cairo University. All animals were handled according to the guidelines established by institutional animal care and use committees. Rats were housed with normal light dark cycle, and were allowed to acclimatize to their environment for five days before start of experiment. All animals were kept under the same environmental conditions and had free access to water and food. The rats were divided into five groups (each group consisted of 10 rats) as follows; group I (control group), group II (Type 1 diabetic rats), group III (Type 2 diabetic rats), group IV (Insulin treated type 1 diabetic rats) and group V (rosiglitazone treated type 2 diabetic rats).

Induction of experimental type 1 diabetes:

Thirty rats were injected intraperitoneally (i.p.) with a single dose of 60 mg/kg of streptozotocin (STZ) (Sigma, Chemical Co., St. Louis, MO, USA) dissolved in sodium citrate buffer (0.1 mol/liter, pH adjusted to 4.5) at a concentration of 20 mg/ml immediately before use [8]. After 3 days, fasting blood samples were collected through the retro-orbital route using capillary tubes to assess glucose level by using a glucometer (Aquo-Check, Roche). Animals showing blood glucose higher than 200 mg/dl were considered as diabetic and twenty of them were used for the study [9].

Induction of experimental type 2 diabetes:

High-fructose diets (HFD) are usually used to induce type 2 diabetes animal model [10]. Thirty rats were fed with high fructose diet (60% fructose) and water for 4 weeks after which fasting blood samples were withdrawn through the retro-orbital route using capillary tubes to assess glucose level. Rats exhibiting plasma glucose more than 200 mg/dl were considered to have type 2 diabetes [9] and twenty of them were used for the study. The animals were kept on the HFD throughout the whole period of the study (for additional four weeks after development of diabetes).

Insulin treatment protocols

Four weeks after streptozotocin injection, diabetic animals were placed on an insulin regimen for four weeks. For these animals, insulin doses were individually adjusted to maintain the euglycemia state. Insulin was given in a dose of 10 IU/kg/day subcutaneously once per day between 9:00 and 11:00 a.m. Diabetic animals whose body weight fell below 90% of initial starting body weight during the in vivo protocol had to be eliminated from the study [11]. However, no animals were eliminated as there was no reduction in their body weight below 90% of the original weight.

Administration of rosiglitazone

Rosiglitazone maleate is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity. After the development of type 2 DM by administration of HFD (the time at which hyperglycemia was confirmed), rosiglitazone was given to the diabetic animals for four weeks. It was given orally in a dose of 10 mg/kg/day dissolved in 10 ml distilled water via intra-gastric tube. This dose was chosen because it has been shown to be the effective therapeutic dose in diabetic rats [12].

Samples Used

Blood samples were withdrawn from all rats through the retro-orbital route using heparinized capillary tubes. The blood samples were delivered into centrifuge tubes then, centrifuged at 10,000 rpm for 20 minutes and plasma was separated and stored at -70°C until used. The plasma was divided into 3 tubes for further determination of plasma levels of glucose, T3, T4, triglycerides (TG) and total cholesterol (TC).

Heart perfusion Conditions

After taking blood samples, all animals were heparinized with 100 U of heparin intraperitoneally (i.p.) for 15 min. Animals were then anesthetized with 10 mg/Kg sodium pentobarbitone (i.p.). The hearts were excised and placed in ice – cold Krebs – Henseleit Bicarbonate (KHB) buffer. Extraneous

tissues (Pericardium, lung, trachea, etc.) were removed. Aorta was cannulated with an 18 – gauge plastic cannula, in a non circulating Langendorff apparatus, with modified Krebs Henseleit solution at a constant flow rate of 12 ml/min. The perfusate solution consists of the following (in mmol/l): NaCl (116), NaHCO₃ (25), CaCl₂ (205), MgSO₄ (102), KCl (407), K H₂PO₄ (102) and glucose (5.5). The Langendorff apparatus was water jacketed to maintain a core temperature of the heart 38°C. The perfusate was oxygenated with 95% O₂ and 5% CO₂ gas mixture to maintain a PO₂ of > 40 mmHg. A water-filled latex balloon-tipped catheter was inserted into the left ventricle through the mitral annulus and inflated with distilled water (0.15 – 0.3 ml) to set an end diastolic pressure of 2 mmHg during the initial equilibration. The distal end of the catheter was connected to a polygraph (san-ei Japan) for recording the different haemodynamic parameters, via pressure transducer, according to the experimental design. Contractile function was assessed by measuring the following parameters: Heart rate (HR), left ventricular developed pressure (LVDP) which is defined as peak systolic minus end-diastolic pressure and the maximum rate of pressure rise (+dp/dt).

Pharmacological drugs used

Rosiglitazone was obtained from Smith Kline Beecham pharmaceuticals, Philadelphia, PA 19101, U.S.A. Long acting protamine zinc insulin (PZI) was purchased from Nile Company (Egypt). Fructose was obtained from Sigma-Aldrich Laborchemik-alien GmbH. D-30976 Seelze.

Biochemical estimation

The blood glucose was assayed by the method adopted by Trinder [13] using kits supplied by Diamond Diagnostics. Fasting plasma TG was assayed by the method previously adopted by Wahlefeld [14] using TG quantification kit supplied by BioVision Research. Fasting plasma cholesterol was assayed by the method previously described by Sundvall et al. [15] using cholesterol assay kit

supplied by BioAssay Systems. Plasma total T3 and T4 concentrations were determined by radioimmunoassay methods adopted by Burtis and Ashwood [16] using reagent kits purchased from Diagnostic Systems Laboratories (USA).

Statistical Methods

Data were processed using the Statistical Package for Social Sciences® (SPSS) program v. 20 (Chicago, IL, USA). Descriptive statistics were used, as means (M) and standard deviations (SD), frequency distribution, and comparisons. One way ANOVA test was used to compare between groups, followed by post hoc test (least significant difference) for inter-group comparisons. We considered differences to be statistically significant if P values were < 0.05.

Results

1. Effect of induction of diabetes and its treatment with insulin and rosiglitazone on blood glucose, plasma triglycerides and total cholesterol levels in type 1 and type 2 diabetes respectively (Table 1).

In group II, the induction of type 1 diabetes resulted in significant increase in blood glucose, plasma TG and TC as compared with group I. Similarly, the same changes are observed in group III (type 2 DM). However, blood glucose and plasma TC was significantly lower, and TG was significantly higher in group III than group II. Treatment of type I diabetic rats with insulin in group III caused significant reduction of blood glucose, plasma TG and TC levels. Also, treatment of type 2 diabetic rats with rosiglitazone in group V produced significant decrease in these parameters. Also, in rosiglitazone treated type 2 diabetic rats (group V) TG was significantly lower compared to insulin treated type1 diabetic rats (group IV). On the other hand, the reverse occurred for plasma TC level as it was significantly higher in group V compared to group IV.

Table 1: Effect of induction of diabetes mellitus and its treatment with insulin and rosiglitazone on blood glucose, plasma triglycerides and total cholesterol levels in type 1 and type 2 diabetes respectively.

	ControlGroup (G1)	Type 1 diabetic rats (G2)	Type 2 diabeticrat (G3)	Type 1 DM with insulin(G4)	Type 2 DM with rosiglitazone (G5)
Glucose (mg/dl)	95.8 ± 14.34	388.7 ± 36.90*	232.60 ± 37.85 #	117.60 ± 29.91 [†]	101.20 ± 10.76 [°]
Triglycerides (mg/dl)	66.1 ± 11.14	140.5 ± 9.58 *	192.3 ± 18.05 #	103.1 ± 2.28 [†]	75.6 ± 7.52 [°]
Total cholesterol (mg/dl)	83.5 ± 7.81	223.3 ± 11.91*	144.3 ± 6.45 #	96.7 ± 6.4 [†]	114.6 ± 4.67 [°]

Data are expressed as mean ± SD. * p < 0.05 group 2 compared with the group 1. # p < 0.05 group 3 compared with the group 1. [†] p < 0.05 group 4 compared with the group 2. [°] p < 0.05 group 5 compared with the group 3.

2. Effect of induction of diabetes and its treatment with insulin and rosiglitazone on plasma tri-iodothyronine (T3) and tetra-iodothyronine (T4) levels in type 1 and type 2 diabetes respectively (Table 2)

The induction of type 1 and type 2 diabetes in

group II and III respectively produced significant decrease in both T3 and T4 plasma levels. However, this reduction is more evident in group II than group III. Treatment of type 1 diabetic rats with insulin (group IV) and type 2 diabetic rats with rosiglitazone (group V) resulted in significant increase in plasma levels of both hormones indicating improvement in thyroid

functions. Also, plasma T3 was significantly lower while, plasma T4 was significantly higher in rosiglitazone treated type 2 diabetic rats (group V), compared to insulin treated type 1 diabetic rats (group IV).

Table 2: Effect of induction of diabetes mellitus and its treatment with insulin and rosiglitazone on plasma tri-iodothyronine (T3) and tetra-iodothyronine (T4) levels in type 1 and type 2 diabetes respectively.

	Control Group (G1)	Type 1 diabetic rats (G2)	Type 2 diabetic rat (G3)	Type 1 DM with insulin (G4)	Type 2 DM with rosiglitazone (G5)
T3 (ng/dl)	285.90 ± 12.37	134.50 ± 11.33 *	189.70 ± 11.50 #	256.60 ± 17.75 †	222 ± 5.68 °
T4 (ug/dl)	7.52 ± 0.80	2.19 ± 0.36 *	4.98 ± 0.21 #	5.09 ± 0.57 †	6.58 ± 0.47 °

Data are expressed as mean ± SD. *p < 0.05 group 2 compared with the group 1. #p < 0.05 group 3 compared with the group 1. † p < 0.05 group 4 compared with the group 2. ° p < 0.05 group 5 compared with the group 3.

3. Effect of induction of diabetes and its treatment with insulin and rosiglitazone on heart rate, left ventricular developed pressure (LVDP) and maximum rate of pressure rise (+dp/dt) in type 1 and type 2 diabetes respectively (Table 3)

In groups II and III, the induction of type 1 and type 2 diabetes by streptozotocin and HFD respectively resulted in significant reduction in heart

rate, left ventricular developed pressure (LVDP) and +dp/dt. Also, LVDP increased significantly in group III compared to group II, while regarding HR and +dp/dt there is no significant differences between the 2 groups. The treatment of group IV with insulin and group V with rosiglitazone produced significant elevation in the same parameters. However, all these parameters were significantly lower in rosiglitazone treated group V diabetic rats compared to insulin treated group IV diabetic rats.

Table 3 : Effect of induction of diabetes mellitus and its treatment with insulin and rosiglitazone on heart rate, left ventricular developed pressure (LVDP) and maximum rate of pressure rise (+dp/dt) in type 1 and type 2 diabetes respectively.

	Control Group (G1)	Type 1 diabetic rats (G2)	Type 2 diabetic rat (G3)	Type 1 DM with insulin (G4)	Type 2 DM with rosiglitazone (G5)
Heart rate (beat/min)	178.60 ± 3.63	92.50 ± 6.88 *	99.40 ± 7.23 #	153.30 ± 10.13 †	104.70 ± 6.075 °
LVDP (mmHg)	100 ± 2.67	23.30 ± 2.98 *	50.90 ± 3.73 #	88.80 ± 2.86 †	69.10 ± 1.20 °
+dp/dt (mmHg/sec)	69.30 ± 2.66	38.70 ± 2.11 *	39.50 ± 2.46 #	61.40 ± 3.10 †	49.80 ± 2.10 °

Data are expressed as mean ± SD. *p < 0.05 group 2 compared with the group 1. #p < 0.05 group 3 compared with the group 1. † p < 0.05 group 4 compared with the group 2. ° p < 0.05 group 5 compared with the group 3.

Discussion

Diabetic cardiomyopathy (DCM) is a clinical condition diagnosed when ventricular dysfunction develops in patients with diabetes in the absence of coronary atherosclerosis and hypertension [17]. It was pointed out that diabetes associated with altered lipid metabolism is commonly accompanied by thyroid dysfunction. This can produce significant metabolic disturbances that share in the mechanisms of DCM [7].

In our study, the untreated diabetic rats (both type 1 & 2) exhibited an altered lipid metabolism manifested by significant increase in plasma level of TG and TC. These changes were in accordance with the work of Dansky et al. who found that both STZ-induced and fructose-induced diabetic rats developed elevations of TG and TC levels [18]. Several factors are likely to be responsible for this diabetic dyslipidemia. As insulin has a profound role in the regulation of key enzymes involved in the lipid and lipoprotein metabolism and due to its role on the synthesis and expression of apolipoproteins in hepatic and extra hepatic tissues, its deficiency or defect in its function affects overall lipid metabolism and lipid profile of various tissues [19]. In addition, a previous study showed that, cholesterol absorption is increased

in insulin dependent diabetes and can be corrected by insulin treatment [20].

Interestingly, we observed in this work that DM especially type 2 showed more hypertriglyceridemia than type 1. This is because of peripheral insulin resistance and increased flux of fatty acids to the liver in type 2 DM. Also, there may be a reduction in total lipoprotein lipase activity or increased concentrations of the lipoprotein lipase inhibiting proteins [21].

Our results also demonstrated a highly significant reduction in plasma level of T3 and T4 in groups II, III respectively relative to control group. This effect of diabetes appears to involve changes in hypothalamic thyrotropin-releasing hormone (TRH) secretion and pituitary thyrotropin (TSH) release [22]. More importantly, this reduction is more evident in type 1 than type 2 as we noticed a higher T3 and T4 in type 2 diabetics (group III) relative to type 1 diabetics (group II). These results were in harmony with the results of another study which reported the same findings [23].

Data of the present work demonstrated that relative to control group I, cardiac mechanical performance was significantly reduced in type 1 and type 2 diabetic hearts (groups II & III respectively). A

highly significant decrease in HR, LVDP and $+dp/dt$ was recorded in both groups signifying that isolated hearts from diabetic rats exhibited a certain degree of DCM. Our results are in agreement with the work of other researchers who reported similar findings in diabetic rats [24,25]. Indeed, alterations of diastolic and systolic function are widely reported in uncomplicated diabetic subjects and often predict the development of other chronic diabetic complications [26].

Although the etiology of myocardial injury and dysfunction in diabetes is not well understood, alteration of energy substrates in the form of excess plasma glucose and lipids can directly or indirectly induce mitochondrial reactive oxygen species (ROS) formation in the myocardium. DCM begins with a disturbance in the glucose metabolism that provokes hyperglycemia. A feature common to all cell types that are damaged by hyperglycemia is an increased production of advanced glycation end products (AGEs) and ROS [27,28]. High concentration of glucose triggers AGEs synthesis, in particular, glycated extra matrix proteins such as collagens. AGEs bind its specific receptors (RAGE) to activate NADPH oxidase (NOX) and to release ROS [29]. Protein kinase C (PKC) can also be stimulated by AGEs to phosphorylate proteins involved in Ca^{2+} handling and cardiomyocyte contraction [30, 31]. In addition, acute exposure to high glucose elevates inducible nitric oxide synthase (iNOS gene) expression and subsequent nitric oxide (NO), and peroxynitrite (ONOO⁻), which in turn stimulate poly-ADP ribose-polymerase-1 enzyme (PARP) as a compensatory antioxidant mechanism [32]. Increased accumulation of fatty acids (FAs) and their derivatives fatty acyl CoA, diacylglycerol (DAG), and ceramide dampens insulin signaling through activation of serine kinases such as protein kinase C [33]. Another target of free FAs in cardiomyocytes is the peroxisome proliferator-activated receptors- α (PPAR- α) pathway. An increase in PPAR- α expression was reported in almost all rodent models of DCM [34].

The dramatic accumulation of intramyocardial lipids in the diabetic heart led to the hypothesis of "toxic lipids" as mediators of cardiac dysfunction in DCM [35]. Accumulation of ceramide and diacylglycerol (DAG) has been demonstrated to alter intracellular signaling pathways and promote apoptotic cell death [36]. On sympathetic activation, augmented accumulation of norepinephrine, increased oxidative stress, and apoptosis may have contributed to abnormal vascular reactivity [37].

Moreover, the pathogenesis of myocardial dysfunction in diabetes can be explained by defects in calcium signaling. It was reported that the reduced L-type Ca^{2+} current density in myocytes from diabetic mice is partly due to reduced cell surface expression of the L-type Ca^{2+} channel [38]. The release of calcium ions from internal sarcoplasmic reticulum via type 2 ryanodine receptor calcium-release channel is

an integral step in the cascade of events leading to cardiac muscle contraction [39]. Other potential mechanism is that the decrease in LVDP might be due to increased collagen deposition or increased glucose-mediated collagen cross-linking in diabetic mice independent of myocyte pathology [40].

The decreased myocardial performance observed in our study can be explained by significant decrease in the levels of T3 and T4 as observed in both type 1 and type 2 diabetic rats [41]. As diabetic animals had decreased values of circulating thyroid hormones and similar diminished thyroid hormone levels have been observed in humans with diabetes. The observed Hypothyroidism could induce cardiac remodeling in 3 ways; Firstly, by decreasing the activity of some enzymes included in intracellular calcium handling which further changes the expression of contractile protein [42]. Secondly, chronic inflammation [43] and tissue changes such as collagen alteration, dehydration or capillary distribution [44]. Thirdly, subclinical hypothyroidism is associated with hemodynamic changes that could also induce cardiac impairment [45]. In addition to the above-mentioned mechanisms that could induce LV dysfunction, increased systemic vascular resistance [46] and activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system could also have a significant role in hemodynamic and structural changes of the LV [47].

In an attempt to assess the role of the different altered metabolic parameters on myocardial function, we compared the cardiac mechanical efficiency in both type 1 and type 2 diabetic rats. We found that LVDP in type 2 was significantly higher than in type 1 diabetic rats, while there was no significant difference in heart rate and $+dp/dt$. In support of our study, a previous research demonstrated that impaired LVDP and mechanical efficiency are maintained in type 2 more than type 1 diabetic mice [48].

Compared to non treated type 1 diabetic rats, treatment with insulin in group IV produced a highly significant decrease of blood glucose level and this improvement reached nearly normal level as no significant difference was observed relative to control group. Concerning the thyroid hormones, T3 and T4 levels were significantly increased in treated group IV as compared to non treated group II. While relative to control group, T3 and T4 levels were still significantly low. Improvement of thyroid hormones levels as observed in insulin treated type 1 diabetic rats was in agreement with Kosova et al. who noticed that there was a significant decrease in serum level of thyroid hormones in type 1 STZ induced diabetic rats and this decrease was greatly corrected after prompt subcutaneous insulin therapy [49]. One of the contributing factors involved in the hypothyroid state observed in diabetics are the changes that occur in hypothalamic TRH secretion as well as changes in pituitary thyrotropin hormone release. Insulin therapy

can normalize the hypothalamo-pituitary-thyroid axis, and increase the iodide trapping to thyroid gland in diabetic models [50].

Regarding mechanical cardiac performance, we found that insulin treatment of type 1 diabetic rats (group IV) resulted in a highly significant improvement of HR, LVDP, and +dp/dt compared to non treated type 1 diabetic rat (group II). However, relative to control group a significant difference still existed. These data suggest that type 1 diabetes results in progressive marked changes in the myocardium that can be prevented or improved by early insulin treatment. These results are consistent with the results of several authors who proved that insulin therapy for type 1 diabetic rats can improve the mechanical parameters of the heart and the metabolic dysfunction accompanying diabetes [3,51,52]. Several studies explained the protective effect of insulin on the heart as follows: the decrease in cardiac contractility induced by chronic diabetes results in part from decrease in expression and alteration in function of ryanodine type 2 calcium release channel in cardiac myocyte and these changes can be reversed by insulin treatment [53].

Although insulin increases transport of glucose into the cardiac myocytes, it has been demonstrated that insulin promotes a positive inotropic effect independent of glucose uptake [54]. Increasing evidence indicates that, in addition to its inimitable function in glucose metabolism, insulin plays critical roles in a variety of other physiological and pathological modulations, such as regulation of inflammatory response and nitric oxide production [55]. The improvement of cardiac power and metabolic parameters by insulin is due to overexpression of glucose transporter 4 (GLUT-4) [56]. In addition, in the mice insulin therapy has been found to increase T cell production of interleukin-4 (IL-4), a cytokine associated with protection against diabetic ischemic heart [57]. Inukai reported that insulin affects the activity of genes that have insulin-responsive regions in their promoters in heart [58]. The discovered Insulin-Induced genes (Insig) may be responsible for other insulin mediated cardiac effects [59]. Furthermore, increased norepinephrine content in diabetic myocardium was completely prevented by insulin therapy started immediately after streptozotocin injection [60]. The altered pattern of substrate metabolism was restored to normal in perfused hearts from insulin treated rats, and contractile function was normalized even though signs of diabetes (hyperglycemia and hyperlipidemia) were still evident, indicating that altered cardiac metabolism is an important causative factor in the contractile dysfunction [61].

Concerning rosiglitazone treatment of type 2 diabetes (group V) for one month, we found that this drug produced highly significant decrease in blood glucose compared to non treated rats and with no significant difference relative to control rats.

Rosiglitazone also produced highly significant decrease of plasma TG and TC levels as compared to non treated type 2 diabetic rats but still significantly lower than the normal rats. Rosiglitazone also affected the plasma levels of T3 and T4 as we noticed a significant increase in their levels, but this improvement was still significantly lower than the normal control levels.

Our results demonstrated that rosiglitazone improves the insulin sensitivity as it lowers the blood glucose level. Also, it improves the plasma level of TG more than TC level and elevates T3 and T4 levels as compared to untreated type 2 diabetic rats. Serum metabolic and lipoprotein subclass changes, which may be associated with this rosiglitazone-induced improvement may occur through the binding of rosiglitazone to peroxisome proliferator activated receptor gamma (PPAR γ) resulting in improved insulin sensitivity and redistribution of adipose tissue.

Also, it was reported that rosiglitazone not only improved the insulin action, but also improved β – cells function [62]. Moreover, it decreased circulating TG, FFA and TC levels in rats without altering the total weight of white adipose tissue [63]. In addition, rosiglitazone might have an enhanced rate of TG removal by reducing insulin resistance in peripheral tissues and increasing the action of insulin on lipoprotein lipase (LPL) [64]. Our results also revealed a rising effect of rosiglitazone on thyroid hormones. This may be due to the direct effect of rosiglitazone on the thyroid gland through increasing its iodide trapping and binding and enhancing all the process of thyroid hormones synthesis [65].

Also, this explanation was confirmed by the Western blot studies with the sodium iodide symporter (NIS) which showed that rosiglitazone effect on iodide transport is expressed, at least in part, by an increased thyroid tissue content of the NIS transporter [66]. Our results are in agreement with other researchers work who demonstrated that rosiglitazone has an improving effect on cardiac performance [56,67]. Also, the protective effect of rosiglitazone against myocardial diabetic injury was evident by attenuation of decrease in +dp/dt and LVDP rats [68]. Moreover, rosiglitazone produced cardiac protection due to increase in angiotensin II (AT2) receptor mRNA and a marked reduction in angiotensin I (AT1) receptor mRNA. The mechanisms of AT2 receptor-mediated cardioprotection, involve stimulation of protein tyrosine or serine/threonine phosphatases in a Gi protein-dependent manner [69].

Conclusion: We concluded that the induction of both types of diabetes resulted in decreased myocardial performance parameters. The treatment of type 1 and type 2 DM by insulin and oral rosiglitazone respectively improved to a great extent the metabolic disturbances and myocardial contractile function with more improving effect of insulin in type 1 than rosiglitazone in type 2 DM. So, treatment of DM is

very important for improvement of myocardial dysfunction and management of DCM.

References

1. Wu CJ, Sung HC, Chang AM, Atherton J, Kostner K, Courtney M, McPhail SM. Protocol for a randomised blocked design study using telephone and text-messaging to support cardiac patients with diabetes: a cross cultural international collaborative project. *BMC Health Serv Res.* 2013; 13:402.
2. Bugger H, Abel ED. Rodent models of diabetic cardiomyopathy. *Disease Models & Mechanisms.* 2009; 2:454-466.
3. Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic mice. *Am J Physiol Endocrinol Metab.* 2004; 279:1104-13.
4. Sunderesan PR, Sharma VK, Gingold SL. Decreased beta adrenergic receptors in rat heart in streptozotocin induced diabetes: Role of thyroid hormones. *Endocrinol.* 1984; 114:1358-1363.
5. Hirayama H, Sugano M, Abe N, Yonemochi H, Makino N. Torglitazone an antidiabetic drug improves left ventricular mass and diastolic function in normotensive diabetic patients. *Int J Cardiol.* 2006; 77:75-9.
6. Falzacappa CV, Mangialardo C, Madaro L, Ranieri D, Lupoi L, Stigliano A, Torrisi MR, Bouché M, Toscano V, Misiti S. Thyroid hormone T3 counteracts STZ induced diabetes in mouse. *Plos One.* 2011; 6 (5):e19839.
7. Peppas M, Betsi G, Dimitriadis G. Lipid abnormalities and cardiometabolic risk in patients with overt and subclinical thyroid disease. *J Lipids.* 2011;2011:575840.
8. Keshor M, Takanda J, Roterto L. Ischemic heart disease: diabetes and vascular risk. *Am J Cardiol.* 2004; 4: 254-315.
9. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat. A model for type 2 diabetes and pharmacological screening. *Pharmacol Res.* 2005; 52:313 – 320.
10. Huang BW, Chiang MT, Yao HT, Chiang W. The effect of high-fat and high-fructose diets on glucose tolerance and plasma lipid and leptin levels in rats. *Diabetes Obes Metab.* 2004; 6(2):120-6.
11. Zhang L, Parratt JR, Beastall GH, Pyne NJ, Furman BL. Streptozotocin diabetes protects against arrhythmias in rat isolated heart, role of hypothyroidism. *Eur J Pharmacol.* 2002; 25:43-269.
12. Takazawa T, Yamauchi T, Tsuchida A, Takata M, Hada Y, Iwabu M, Okada-Iwabu M, Ueki K, Kadowaki T. Peroxisome Proliferator-activated Receptor γ Agonist Rosiglitazone Increases Expression of Very Low Density Lipoprotein Receptor Gene in Adipocytes. *J Biol Chem.* 2009; 284:30049-30057.
13. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. *Ann Clin Biochem.* 1969; 6:24.
14. Wahlefeld AW. Triglyceride determination after enzymatic hydrolysis. In *Methods of Enzymatic Analysis* (Bermeyer, H.U., Eds.), Academic press, New York, 1974: pp. 18-31.
15. Sundvall J, Leiviskä J, Alfthan G, Vartiainen E. Serum cholesterol during 27 years: assessment of systematic error and affecting factors and their role in interpreting population trends. *Clin Chim Acta.* 2007; 378(1-2):93-8.
16. Burtis CA, Ashwood ER (Eds.). *Tietz textbook of clinical chemistry.* 2nd ed., Philadelphia: W. B. Saunders Company, 1994: pp. 1711-1715.
17. Joffe II, Travers KE, Perreault-Micale CL, et al. Abnormal cardiac function in the streptozotocin-induced, non-insulin dependent diabetic rat. *J Am Coll Cardiol.* 1999; 34(7):2111- 2119.
18. Dansky H, McClain DA, McIndoe R, Wassef MK, Rabadan-Diehl C, Goldberg IJ. Recipes for Creating Animal Models of Diabetic Cardiovascular Disease. *Circ Res.* 2007; 100: 1415-1427.
19. Chaudhuri A, Dandona P. Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes. *Diabetes Obes Metab.* 2011; 13(10):869-79.
20. Després JP, Marette A. Relation of components of insulin resistance syndrome to coronary disease risk. *Curr Opin Lipidol.* 2001; 5:274-289.
21. Virmani R, Burke AP, Kolodgie F. Morphological characteristics of coronary atherosclerosis in diabetes mellitus. *Can J Cardiol.* 2007; 22(Suppl B):81B-84B.
22. Steger RW, Rabe MB. The effect of diabetes mellitus on endocrine and reproductive function. *Proc Soc Exp Biol Med.* 1997; 214(1):1-11.
23. Duntas LH, Orgiazzi J, Brabant G. The Interface Between Thyroid and Diabetes Mellitus. *Clin Endocrinol.* 2011; 75(1):1-9.
24. Lorenzo O, Ramirez E, Picatoste B, Egido J, Tuñón J. Alteration of energy substrates and ROS production in diabetic cardiomyopathy. *Mediators Inflamm.* 2013;2013:461967.
25. Bayeva M, Sawicki KT, Ardehali H. Taking Diabetes to Heart-Deregulation of Myocardial Lipid Metabolism in Diabetic Cardiomyopathy. *J Am Heart Assoc.* 2013; 2:e000433.
26. Carley AN, Severson DL. Fatty acid metabolism is enhanced in type 2 diabetic hearts. *Biochim Biophys Acta.* 2005; 1734(2):112-126.
27. Asrih M, Steffens S. Emerging role of epigenetics and mRNA in diabetic cardiomyopathy. *Cardiovascular Pathology.* 2013; 22:117-125.
28. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. *Diabetes.* 2005; 54(6):1615-1625.
29. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. *Circulation.* 2006; 114(6):597-605.
30. Braz JC, Gregory K, Pathak A et al. PKC- α regulates cardiac contractility and propensity toward heart failure. *Nature Medicine.* 2004; 10(3):248-254.
31. Coughlan MT, Thorburn DR, Penfold SA et al. Rage-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. *J Am Soc Nephrol.* 2009; 20(4):742-752.
32. Ceriello A. Acute hyperglycaemia: a new risk factor during myocardial infarction. *Eur Heart J.* 2005; 26(4):328-331.
33. Sykiotis GP, Papavassiliou AG. Serine phosphorylation of insulin receptor substrate-1: a novel target for the reversal of insulin resistance. *Mol Endocrinol.* 2001; 15:1864-1869.
34. Huang TH, Yang Q, Harada M, Uberai J, Radford J, Li GQ, Yamahara J, Roufogalis BD, Li Y. Salacia oblonga root improves cardiac lipid metabolism in Zucker diabetic fatty rats: modulation of cardiac PPAR- α -mediated transcription of fatty acid metabolic genes. *Toxicol Appl Pharmacol.* 2006; 210:78-85.
35. Van Herpen NA, Schrauwen-Hinderling VB. Lipid accumulation in non adipose tissue and lipotoxicity. *Physiol Behav.* 2008; 94:231-241.
36. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B, Anversa P. Myocardial cell death in human diabetes. *Circ Res.* 2000; 87:1123-1132.
37. Wu QD, Wang JH, Fennessy F, Redmond HP, Bouchier-Hayes D. Taurine prevents high-glucose-induced human vascular endothelial cell apoptosis. *Am J Physiol.* 1999; 277:C1229-38.
38. Zhao XY, Hu SJ, Li J, Mou Y, Chen BP, Xia Q. Decreased cardiac sarcoplasmic reticulum Ca²⁺-ATPase activity contributes to cardiac dysfunction in streptozotocin-induced diabetic rats. *J Physiol Biochem.* 2006;62(1):1-8.
39. Bers DM. Cardiac excitation-contraction coupling. *Nature.* 2002;

415 :198–205.

40. Kaidar A, Marx M, Lubec B, Lubec G. L-arginine reduces heart collagen accumulation in the diabetic db/db mouse. *Circulation*. 2007; 90:479–483.
41. Ilic S, Tadic M, Ivanovic B, Caparevic Z, Trbojevic B, Celic V. Left and right ventricular structure and function in subclinical hypothyroidism: The effects of one-year levothyroxine treatment. *Med Sci Monit*. 2013;10:19:960-8.
42. Rudski LG, Lai WW, Afilalo J et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *J Am Soc Echocardiogr*. 2010; 23(7):685–713.
43. Aksoy D, Cinar N, Harmanci A et al. Serum resistin and high sensitive CRP levels in patients with subclinical hypothyroidism before and after L-thyroxine therapy. *Med Sci Monit*. 2013; 19:210–15.
44. Brenta G, Mutti LA, Schnitman M et al. Assessment of left ventricular diastolic function by radionuclide ventriculography at rest and exercise in subclinical hypothyroidism, and its response to L-thyroxine therapy. *Am J Cardiol*. 2003; 91(11):1327–30.
45. Biondi B, Palmieri EA, Lombardi G, Fazio S. Subclinical hypothyroidism and cardiac function. *Thyroid*. 2002; 12(6):505–10.
46. Jagdish A, Singh H, Batra A et al. An echocardiographic study on the effect of levothyroxine therapy on cardiac function and structure in hypothyroidism. *JACM*. 2009; 10(1–2):27–31.
47. Fommei E, Iervasi G. The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. *J Clin Endocrinol Metab*. 2002; 87(5):1996–2000.
48. Van den Bergh A, Flameng W, Herijgers P. Type II diabetic mice exhibit contractile dysfunction but maintain cardiac output by favourable loading conditions. *Eur J Heart Fail*. 2006; 8(8):777-783.
49. Kosova F, Sepici-Dincel A, Engin A, Memiş L, Koca C, Altan N. The thyroid hormone mediated effects of insulin on serum leptin levels of diabetic rats. *Endocrine*. 2008; 317:22.
50. Sathish R, Mohan V. Diabetes and thyroid disease – A review. *Int J Diabetes Dev Ctries*. 2003; 23:120-3.
51. Jie YU, Hai-feng ZHANG, Feng WU, Qiu-xia LI, Heng MA, Wen-yi GUO, Hai-chang WANG, Feng GAO. Insulin improves cardiomyocyte contractile function through enhancement of SERCA2a activity in simulated ischemia/reperfusion. *Acta Pharmacol Sin*. 2006; 27(7): 919–926.
52. Kim HW, Ch YS, Lee HR, Park SY, Kim YH. Diabetic alterations in cardiac sarcoplasmic reticulum Ca²⁺-ATPase and phospholamban protein expression. *Life Sci*. 2003; 70 :367–379.
53. Bidasee KR, Nallani K, Henry B, Dincer UD, Besch HR Jr. Chronic diabetes alters function and expression of ryanodine receptor calcium-release channels in rat hearts. *Mol Cell Biochem*. 2013; 249(1-2):113-23.
54. Zhang B, Roth RA. A region of the insulin receptor important for ligand binding (residues 450-601) is recognized by patients autoimmune antibodies and inhibitory monoclonal antibodies. *Proc Natl Acad Sci*. 2006; 88:9858-9862.
55. Jeschke MG, Klein D, Bolder U, Einspanier R. Insulin attenuates the systemic inflammatory response in endotoxemic rats. *Endocrinology*. 2004; 145: 4084–93.
56. Belke DD, Swanson EA, Dillmann WH. Decreased Sarcoplasmic Reticulum Activity and Contractility in Diabetic *db/db* Mouse Heart. *Diabetes*. 2004; 53:3201-3208.
57. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed type I insulin-dependent diabetes mellitus. *N Engl J Med*. 2006; 320:550-554.
58. Inukai K. P85 α gene generates three isoforms of regulatory subunit for phosphatidylinositol-3 kinase (PI3-kinase) p50 α , with different PI3-kinase activity elevating responses to insulin. *J Biol Chem*. 2005; 272:7873-7882.
59. Artie AD. Insig: a significant integrator of nutrient and hormonal signals. *J Clin Invest*. 2004; 113:1112–1114.
60. Carpino N. P62 dok: a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. *Cell*. 2005; 88:197-204.
61. Krook A, O'Rahilly S. Mutant insulin receptors in syndromes of insulin resistance (review). *Endocr Metab*. 2006; 10:97-122.
62. Ovalle F, Bell DSH. Effect of Rosiglitazone Versus Insulin on the Pancreatic β -Cell Function of Subjects With Type 2 Diabetes. *Diabetes Care*. 2004; 27(11):2585-2589.
63. Kumar J, Liebel R. To eat or not to eat-how the gut talks to the brain. *NEJM*. 2004; 349:926-928.
64. Sahin M, Tutuncu NB, Ertugrul D, Tanaci M, Guvener ND. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B 12 in patients with type 2 diabetes mellitus. *J Diabetes Complications*. 2007; 21(2):118-23.
65. Tepmongkol S, Keelawat S, Honsawek S, Ruangvejvorachai P. Rosiglitazone Effect on Radioiodine Uptake in Thyroid Carcinoma Patients with High Thyroglobulin but Negative Total Body Scan: A Correlation with the Expression of Peroxisome Proliferator-Activated Receptor-Gamma. *Thyroid*. 2008; 18(7):697-704.
66. Rillema JA, Williams CH, Moulden J, Golden KL. Effect of insulin on iodide uptake in mouse mammary gland explants. *Exp Biol Med*. (Maywood). 2002; 227(1):32-5.
67. Dong MJ, Akinari T, Hayato N, Ken-Ichiro F, Toshiharu A. Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes. *Metab*. 2006; 49:1167-1175.
68. Yang B, Li D, Phillips MI, Mehta P, Mehta JL. Myocardial angiotensin II receptor expression and ischemia-reperfusion injury. *Vasc Med*. 2005; 3:121–130.
69. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor- γ . *Circulation*. 2007; 105:2296–2302.